

Time Inc.
Form SC TO-T/A
January 12, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO
(RULE 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)

TIME INC.
(Name of Subject Company (Issuer))
GOTHAM MERGER SUB, INC.
(Name of Filing Persons (Offeror)) a wholly owned subsidiary of
MEREDITH CORPORATION
(Name of Filing Persons (Parent of Offeror))

Common Stock, \$0.01 par value per share
(Title of Class of Securities)

887228104

(CUSIP Number of Class of Securities)

Gotham Merger Sub, Inc.

c/o Meredith Corporation

1716 Locust Street

Des Moines, Iowa 50309

(515) 284-3000

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing person)

Copy to:

J. Kevin Mills

Cooley LLP

1299 Pennsylvania Avenue, NW, Suite 700

Washington, DC 20004

(202) 842-7800

CALCULATION OF FILING FEE

Transaction valuation*
\$1,913,394,167.55

Amount of filing fee**
\$238,217.57

- * Estimated solely for purposes of calculating the filing fee. This calculation is based on the offer to purchase all of the issued and outstanding shares of common stock, \$0.01 par value per share (the **Shares**), of Time Inc., at a purchase price of \$18.50 per Share, without interest thereon, net to the seller in cash and subject to reduction for any applicable U.S. federal withholding, back-up withholding or other applicable tax withholdings. The underlying value of the transaction was calculated based on the sum of: (i) 99,622,569 issued and outstanding Shares, multiplied by \$18.50 per Share; (ii) 5,704,765 Shares issuable pursuant to outstanding options with an exercise price that is less than \$18.50 per Share, multiplied by \$1.17 per Share (which is equal to the difference between \$18.50 and \$17.33, the weighted average exercise price of such options that have an exercise price that is less than \$18.50 per Share); (iii) 2,501,866 Shares issuable pursuant to outstanding restricted stock units, multiplied by \$18.50 per Share; (iv) 306,825 Shares issuable pursuant to certain outstanding performance stock units, multiplied by \$18.50 per Share; (v) 177,079 Shares issuable pursuant to certain earned performance stock units, multiplied by \$18.50 per Share; (vi) 178,666 Shares issuable pursuant to outstanding deferred stock units, multiplied by \$18.50 per Share; and (vii) 1,200,000 Shares issuable pursuant to certain outstanding options, multiplied by \$4.30 per Share (which is equal to the difference between \$18.50 and \$14.20, the exercise price of such options).
- ** The filing fee, calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year 2018, issued August 24, 2017 is calculated by multiplying the transaction valuation by 0.0001245.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:	\$238,217.57	Filing party:	Gotham Merger Sub, Inc. and Meredith Corporation
Form or Registration No.:	Schedule TO	Date filed:	December 12, 2017
(File No. 005-88270)			

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.

This Amendment No. 4 (this **Amendment**) amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission on December 12, 2017 (together with any subsequent amendments and supplements hereto, the **Schedule TO**). The Schedule TO relates to the tender offer by Gotham Merger Sub, Inc., a Delaware corporation (**Purchaser**) and a wholly owned subsidiary of Meredith Corporation, an Iowa corporation (**Parent**), for all of the outstanding shares of common stock, \$0.01 par value per share (the **Shares**) of Time Inc., a Delaware corporation (the **Company**), at a price of \$18.50 per Share, without interest thereon, net to the seller in cash, and subject to reduction for any applicable U.S. federal withholding, back-up withholding or other applicable tax withholdings, upon the terms and conditions set forth in the offer to purchase dated December 12, 2017 (together with any amendments and supplements thereto, the **Offer to Purchase**), a copy of which is attached as Exhibit (a)(1)(A) to the Schedule TO, and in the related letter of transmittal (the **Letter of Transmittal**), a copy of which is attached as Exhibit (a)(1)(B) to the Schedule TO, which, together with any other related materials, as each may be amended or supplemented from time to time, collectively constitute the **Offer**, pursuant to an Agreement and Plan of Merger, dated as of November 26, 2017 (as it may be amended from time to time, the **Merger Agreement**), by and among Purchaser, Parent and the Company.

All of the information set forth in the Offer to Purchase, including all schedules thereto, is hereby expressly incorporated herein by reference to all of the applicable items in the Schedule TO, except that such information is amended and supplemented to the extent specifically provided in this Amendment. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Offer to Purchase or in the Schedule TO.

This Amendment is being filed to amend and supplement Items 11 and 12 as reflected below.

Item 11. Additional Information.

Item 11 of the Schedule TO and the disclosure under Section 16 **Certain Legal Matters; Regulatory Approvals** of the Offer to Purchase are hereby amended and supplemented by inserting the following text to the end of the second paragraph to the subsection titled **Antitrust Compliance** :

On January 12, 2018, early termination of the applicable waiting period under the HSR Act was granted. Accordingly, the condition of the Offer relating to the expiration or termination of the HSR Act waiting period has been satisfied. The Offer continues to be subject to the remaining terms and conditions set forth in this Offer to Purchase.

Item 12. Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit thereto:

Exhibit No.	Description
(a)(5)(C)	Press Release issued by Meredith Corporation, dated January 12, 2018

SIGNATURES

After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: January 12, 2018

GOTHAM MERGER SUB, INC.

By: /s/ Joseph Ceryanec
Name: Joseph Ceryanec
Title: President

MEREDITH CORPORATION

By: /s/ Joseph Ceryanec
Name: Joseph Ceryanec
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
(a)(1)(A)	Offer to Purchase, dated December 12, 2017*
(a)(1)(B)	Form of Letter of Transmittal (including Internal Revenue Service Form W-9)*
(a)(1)(C)	Form of Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees*
(a)(1)(D)	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees*
(a)(1)(E)	Form of Notice of Guaranteed Delivery*
(a)(1)(F)	Summary Advertisement as published in the New York Times on December 12, 2017*
(a)(5)	Press Release issued by Meredith Corporation, dated November 26, 2017 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Meredith Corporation (File No. 001-05128) with the Securities and Exchange Commission on November 27, 2017)
(a)(5)(B)	Press Release issued by Meredith Corporation, dated January 11, 2018*
(a)(5)(C)	Press Release issued by Meredith Corporation, dated January 12, 2018
(b)(1)	Commitment Letter, dated November 26, 2017, by and among Meredith Corporation, Royal Bank of Canada, RBC Capital Markets, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Barclays Bank PLC and Citigroup Global Markets Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Meredith Corporation (File No. 001-05128) with the Securities and Exchange Commission on November 27, 2017)
(b)(2)	Equity Commitment Letter, dated November 26, 2017, by and among Meredith Corporation and Koch Equity Development LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Meredith Corporation (File No. 001-05128) with the Securities and Exchange Commission on November 27, 2017)
(d)(1)	Agreement and Plan of Merger, dated as of November 26, 2017, by and among Meredith Corporation, Gotham Merger Sub, Inc. and Time Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Meredith Corporation (File No. 001-05128) with the Securities and Exchange Commission on November 27, 2017)
(d)(2)	Confidentiality Agreement, dated February 4, 2017, between Time Inc. and Meredith Corporation*

* Previously filed.

:bottom;background-color:#cceeef;">

\$

0.71

Basic weighted average shares outstanding

344,431

341,788

343,880

342,787

Diluted weighted average shares outstanding
352,450

349,794

352,162

351,049

See notes to condensed consolidated financial statements (unaudited).

2

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
 For the three and six months ended July 4, 2015 and June 28, 2014
 (unaudited)

(In thousands)	Three Months Ended		Six Months Ended	
	2015	2014	2015	2014
Net earnings	\$ 115,038	\$ 129,033	\$ 225,972	\$ 248,559
Foreign currency translation adjustment and other (net of taxes (benefit) of \$(863) and \$(2,229) for the three and six months ended July 4, 2015; and \$(48) and \$319 for the three and six months ended June 28, 2014)	5,616	5,042	(12,894)	8,069
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of \$(132) and \$113 for the three and six months ended July 4, 2015; and \$(55) and \$7 for the three and six months ended June 28, 2014)	(212)	(85)	174	12
Comprehensive income	\$ 120,442	\$ 133,990	\$ 213,252	\$ 256,640

See notes to condensed consolidated financial statements (unaudited).

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 For the six months ended July 4, 2015 and June 28, 2014
 (unaudited)

(In thousands)	Six Months Ended	
	2015	2014
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net earnings	\$225,972	\$248,559
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	213,513	141,806
Share-based compensation expense	34,451	28,269
Provision for deferred income taxes	2,866	2,687
Changes in assets and liabilities (net of businesses acquired):		
Receivables, net	(130,242)	(15,218)
Inventory	423	579
Prepaid expenses and other	(37,951)	11,717
Accounts payable	(4,069)	(518)
Accrued income taxes	(4,667)	(4,864)
Deferred revenue	1,139	17,801
Other accrued liabilities	21,476	(26,760)
Net cash provided by operating activities	322,911	404,058
CASH FLOWS FROM INVESTING ACTIVITIES:		
Capital purchases	(167,134)	(131,997)
Capitalized software development costs	(132,864)	(86,666)
Purchases of investments	(317,890)	(500,903)
Sales and maturities of investments	766,017	572,293
Purchase of other intangibles	(6,895)	(7,190)
Acquisition of businesses	(1,372,014)	(7,476)
Net cash used in investing activities	(1,230,780)	(161,939)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Long-term debt issuance	500,000	—
Repayment of long-term debt and capital lease obligations	—	(69)
Proceeds from excess tax benefits from share-based compensation	52,075	20,642
Proceeds from exercise of options	32,832	14,175
Treasury stock purchases	—	(217,082)
Contingent consideration payments for acquisition of businesses	(11,012)	—
Cash grants	—	48,000
Other	(791)	2,894
Net cash provided by (used in) financing activities	573,104	(131,440)
Effect of exchange rate changes on cash and cash equivalents	(6,459)	2,204
Net increase (decrease) in cash and cash equivalents	(341,224)	112,883

Edgar Filing: Time Inc. - Form SC TO-T/A

Cash and cash equivalents at beginning of period	635,203	202,377
Cash and cash equivalents at end of period	\$293,979	\$315,260
Summary of acquisition transactions:		
Fair value of tangible assets acquired	\$451,881	\$184
Fair value of intangible assets acquired	637,980	3,800
Fair value of goodwill	449,023	16,785
Less: Fair value of liabilities assumed	(166,870)	(1,693)
Less: Fair value of contingent liability payable	—	(11,600)
Net cash used	\$1,372,014	\$7,476
See notes to condensed consolidated financial statements (unaudited).		

4

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1) Interim Statement Presentation

Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by Cerner Corporation (Cerner, the Company, we, us or our) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K.

In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year.

The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates.

Fiscal Period End

Our 2015 and 2014 second quarters ended on July 4, 2015 and June 28, 2014, respectively. All references to years in these notes to condensed consolidated financial statements represent the respective three or six months ended on such dates, unless otherwise noted.

Factors Impacting Comparability of Interim Financial Statements

Siemens Health Services

On February 2, 2015, we acquired Siemens Health Services, as further described in Note (2). The addition of the Siemens Health Services business has a significant impact on the comparability of our condensed consolidated financial statements as of and for the three and six months ended July 4, 2015, in relation to the comparative periods presented herein.

Amortization of Acquisition-related Intangibles

Amortization of acquisition-related intangibles includes the amortization of customer relationships, acquired technology, trade names, and non-compete agreements recorded in connection with our business acquisitions. Historically, such amounts were included in general and administrative expense in our condensed consolidated statements of operations. Effective for our second quarter of 2015, amortization of acquisition-related intangibles is presented on a separate line within our condensed consolidated statements of operations. While this reporting change did not impact our consolidated results, prior period reclassifications have been made to conform to the current period presentation.

Acquisition Transactions within our Condensed Consolidated Statements of Cash Flows

Historically, the fair value of tangible assets acquired and liabilities assumed in business acquisitions were presented on a net basis within our condensed consolidated statements of cash flows. Effective for our first quarter of 2015, the fair value of tangible assets acquired and the fair value of liabilities assumed are presented separately. While this reporting change did not impact our consolidated results, prior period reclassifications have been made to conform to the current period presentation.

Voluntary Separation Plan

In the first quarter of 2015, the Company adopted a voluntary separation plan ("VSP") for eligible associates. Generally, the VSP was available to U.S. associates who met a minimum level of combined age and tenure, excluding, among others, our

Table of Contents

executive officers. Associates who elected to participate in the VSP receive financial benefits commensurate with their tenure and position, along with vacation payout and medical benefits.

We account for voluntary separation benefits in accordance with the provisions of Accounting Standards Codification (ASC) Topic 712, Compensation-Nonretirement Postemployment Benefits. Voluntary separation benefits are recorded to expense when the associates irrevocably accept the offer and the amount of the termination liability is reasonably estimable. The irrevocable acceptance period for most associates electing to participate in the VSP ended in May 2015. In the second quarter of 2015, we recorded a pre-tax charge for the VSP of \$42 million, which is included in general and administrative expense in our condensed consolidated statements of operations. We expect to record additional pre-tax charges for the VSP during the remainder of 2015 of approximately \$4 million, in the aggregate.

Recently Issued Accounting Pronouncements

Revenue Recognition. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP. The new standard is effective for the Company in the first quarter of 2018. The standard permits the use of either the retrospective or cumulative effect transition method. At this time, we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures.

Debt Issuance Costs. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying value of the debt liability. ASU 2015-03 is effective for the Company in the first quarter of 2016, with early adoption permitted, and retrospective application required. The Company has chosen to adopt the standard early, effective in the first quarter of 2015. The adoption of ASU 2015-03 did not have a material impact on our condensed consolidated financial statements. Refer to Note (9) for further information regarding debt issuance costs.

Consolidation. In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which provides guidance when evaluating whether to consolidate certain legal entities. The updated guidance modifies evaluation criteria of limited partnerships and similar legal entities, eliminates the presumption that a general partner should consolidate a limited partnership, and affects the consolidation analysis of reporting entities that are involved with variable interest entities, particularly those that have fee arrangements and related party relationships. ASU 2015-02 is effective for the Company in the first quarter of 2016, with early adoption permitted. We are currently evaluating the effect that ASU 2015-02 will have on our consolidated financial statements and related disclosures.

(2) Business Acquisitions

Siemens Health Services

On February 2, 2015, we acquired substantially all of the assets, and assumed certain liabilities of Siemens Health Services, the health information technology business unit of Siemens AG, a stock corporation established under the laws of Germany, and its affiliates. Siemens Health Services offered a portfolio of enterprise-level clinical and financial health care information technology solutions, as well as departmental, connectivity, population health, and care coordination solutions globally. Solutions were offered on the Soarian®, Invision®, and i.s.h.med® platforms, among others. Siemens Health Services also offered a range of complementary services including support, hosting, managed services, implementation services, and strategic consulting.

We believe the acquisition enhances our organic growth opportunities as it provides us a larger base into which we can sell our combined portfolio of solutions and services. The acquisition also augments our non-U.S. footprint and growth opportunities, increases our scale for R&D investment, and adds over 5,000 highly-skilled associates that will enhance our capabilities. These factors, combined with the synergies and economies of scale expected from combining the operations of Cerner and Siemens Health Services, are the basis for the acquisition and comprise the resulting goodwill recorded.

Consideration for the acquisition was \$1.37 billion of cash, consisting of the \$1.3 billion agreed upon purchase price plus working capital adjustments. The purchase price is subject to certain post-closing adjustments for working capital and pension obligations, as specified in the Master Sale and Purchase Agreement dated August 5, 2014, as amended.

Table of Contents

During the six months ended July 4, 2015, we incurred \$20 million of pre-tax acquisition costs in connection with the acquisition of Siemens Health Services, which are included in general and administrative expenses in our condensed consolidated statements of operations.

The acquisition of Siemens Health Services is being treated as a purchase in accordance with ASC Topic 805, Business Combinations, which requires allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed in the transaction. Our allocation of purchase price is based on management's judgment after evaluating several factors, including a preliminary valuation assessment. The allocation of purchase price is preliminary and subject to changes, which could be significant, as appraisals of tangible and intangible assets are finalized, working capital and pension obligation adjustments are agreed upon and finalized, and additional information becomes available.

The preliminary allocation of purchase price is as follows:

(in thousands)	Allocation Amount	Estimated Weighted Average Useful Life
Receivables, net of allowances of \$33,674	\$236,491	
Other current assets	56,859	
Property and equipment	158,298	20 years
Goodwill	449,023	
Intangible assets:		
Customer relationships	396,000	10 years
Existing technologies	201,990	5 years
Trade names	39,990	8 years
Total intangible assets	637,980	
Other non-current assets	233	
Accounts payable	(42,076))
Deferred revenue (current)	(90,148))
Other current liabilities	(19,716))
Deferred revenue (non-current)	(14,930))
Total purchase price	\$1,372,014	

The intangible assets in the table above are being amortized on a straight-line basis over their estimated useful lives, with such amortization included in amortization of acquisition-related intangibles in our condensed consolidated statements of operations.

The fair value measurements of tangible and intangible assets and liabilities were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value measurement hierarchy. Level 3 inputs included, among others, discount rates that we estimated would be used by a market participant in valuing these assets and liabilities, projections of revenues and cash flows, client attrition rates, royalty rates, and market comparables.

Property and equipment was valued primarily using the sales comparison method, a form of the market approach, in which the value is derived by evaluating the market prices of assets with comparable features such as size, location, condition and age. Our analysis included multiple property categories, including land, buildings, and personal property and included assumptions for market prices of comparable assets, and physical and economic obsolescence, among others.

Customer relationship intangible assets were valued using the excess earnings method, a form of the income approach, in which the value is derived by estimation of the after-tax cash flows specifically attributable to the customer relationships. Our analysis consisted of two customer categories, order backlog and existing customer relationships and included assumptions for projections of revenues and expenses, contributory asset charges, discount rates, and a tax amortization benefit, among others.

Existing technology and trade name intangible assets were valued using the relief from royalty method, a form of the income approach, in which the value is derived by estimation of the after-tax royalty savings attributable to owning the assets.

Table of Contents

Assumptions in these analyses included projections of revenues, royalty rates representing costs avoided due to ownership of the assets, discount rates, and a tax amortization benefit.

Deferred revenue was valued using an income approach, in which the value was derived by estimation of the fulfillment cost, plus a normal profit margin (which excludes any selling margin), for performance obligations assumed in the acquisition. Assumptions included estimations of costs incurred to fulfill the obligations, profit margins a market participant would expect to receive, and a discount rate.

The goodwill of \$449 million was allocated among our Domestic and Global operating segments, as shown below, and is expected to be deductible for tax purposes.

The changes in the carrying amounts of goodwill for the six months ended July 4, 2015 were as follows:

(In thousands)	Domestic	Global	Total
Beginning balance	\$311,170	\$9,368	\$320,538
Goodwill recorded in connection with the Siemens Health Services acquisition	386,663	62,360	449,023
Foreign currency translation adjustments and other	—	(3,515)	(3,515)
Ending balance at July 4, 2015	\$697,833	\$68,213	\$766,046

Our condensed consolidated statements of operations for the three and six months ended July 4, 2015 include revenues of approximately \$260 million and \$435 million, respectively, attributable to the acquired business (now referred to as "Cerner Health Services") since the February 2, 2015 acquisition date. Disclosure of the earnings contribution from the Cerner Health Services business is not practicable, as we have already integrated operations in many areas.

The following table provides unaudited pro forma results of operations for the three and six months ended July 4, 2015 and June 28, 2014, as if the acquisition had been completed on the first day of our 2014 fiscal year.

(In thousands, except per share data)	Three Months Ended		Six Months Ended	
	2015	2014	2015	2014
Pro forma revenues	\$1,125,997	\$1,144,861	\$2,215,766	\$2,210,662
Pro forma net earnings	117,047	115,043	231,379	213,132
Pro forma diluted earnings per share	0.33	0.33	0.66	0.61

These pro forma results are based on estimates and assumptions, which we believe are reasonable. They are not the results that would have been realized had we been a combined company during the periods presented, nor are they indicative of our consolidated results of operations in future periods. The pro forma results for the three months ended July 4, 2015 include a pre-tax adjustment to eliminate \$3 million of acquisition costs. The pro forma results for the six months ended July 4, 2015 include pre-tax adjustments for amortization of intangible assets, fair value adjustments for deferred revenue, and the elimination of acquisition costs of \$7 million, \$6 million and \$20 million, respectively. Pro forma results for the three months ended June 28, 2014 include pre-tax adjustments for amortization of intangible assets and fair value adjustments for deferred revenue of \$22 million and \$7 million, respectively. The pro forma results for the six months ended June 28, 2014 include pre-tax adjustments for amortization of intangible assets and fair value adjustments for deferred revenue of \$43 million and \$25 million, respectively.

Table of Contents

(3) Fair Value Measurements

We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table details our financial assets measured and recorded at fair value on a recurring basis at July 4, 2015:

(In thousands)

Description	Balance Sheet Classification	Fair Value Measurements Using		
		Level 1	Level 2	Level 3
Money market funds	Cash equivalents	\$67,104	\$—	\$—
Time deposits	Cash equivalents	—	9,412	—
Government and corporate bonds	Cash equivalents	—	2,100	—
Time deposits	Short-term investments	—	51,230	—
Commercial paper	Short-term investments	—	4,600	—
Government and corporate bonds	Short-term investments	—	208,244	—
Government and corporate bonds	Long-term investments	—	282,450	—

The following table details our financial assets measured and recorded at fair value on a recurring basis at January 3, 2015:

(In thousands)

Description	Balance Sheet Classification	Fair Value Measurements Using		
		Level 1	Level 2	Level 3
Money market funds	Cash equivalents	\$189,137	\$—	\$—
Time deposits	Cash equivalents	—	9,989	—
Commercial paper	Cash equivalents	—	115,638	—
Time deposits	Short-term investments	—	52,829	—
Commercial paper	Short-term investments	—	435,544	—
Government and corporate bonds	Short-term investments	—	297,290	—

Government and corporate bonds	Long-term investments	—	218,965	—
--------------------------------	-----------------------	---	---------	---

We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt, including current maturities, at July 4, 2015 and January 3, 2015 was approximately \$525 million and \$15 million, respectively. The carrying amount of such debt at July 4, 2015 and January 3, 2015 was \$514 million and \$14 million, respectively.

Table of Contents

(4) Available-for-sale Investments

Available-for-sale investments at July 4, 2015 were as follows:

(In thousands)	Adjusted Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Cash equivalents:				
Money market funds	\$67,104	\$—	\$—	\$67,104
Time deposits	9,412	—	—	9,412
Government and corporate bonds	2,100	—	—	2,100
Total cash equivalents	78,616	—	—	78,616
Short-term investments:				
Time deposits	51,230	—	—	51,230
Commercial paper	4,600	—	—	4,600
Government and corporate bonds	208,202	75	(33)	208,244
Total short-term investments	264,032	75	(33)	264,074
Long-term investments:				
Government and corporate bonds	282,713	79	(342)	282,450
Total available-for-sale investments	\$625,361	\$ 154	\$ (375)	\$625,140

Available-for-sale investments at January 3, 2015 were as follows:

(In thousands)	Adjusted Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Cash equivalents:				
Money market funds	\$189,137	\$—	\$—	\$189,137
Time deposits	9,989	—	—	9,989
Commercial paper	115,638	—	—	115,638
Total cash equivalents	314,764	—	—	314,764
Short-term investments:				
Time deposits	52,830	—	(1)	52,829
Commercial paper	435,555	1	(12)	435,544
Government and corporate bonds	297,311	69	(90)	297,290
Total short-term investments	785,696	70	(103)	785,663
Long-term investments:				
Government and corporate bonds	219,439	26	(500)	218,965
Total available-for-sale investments	\$1,319,899	\$ 96	\$ (603)	\$1,319,392

We sold available-for-sale investments for proceeds of \$57 million and \$156 million during the six months ended July 4, 2015 and June 28, 2014, respectively, resulting in insignificant gains in each period.

Table of Contents

(5) Receivables

A summary of net receivables is as follows:

(In thousands)	July 4, 2015	January 3, 2015
Gross accounts receivable	\$1,009,179	\$641,160
Less: Allowance for doubtful accounts	50,808	25,531
Accounts receivable, net of allowance	958,371	615,629
Current portion of lease receivables	44,772	57,149
Total receivables, net	\$1,003,143	\$672,778

During the second quarter of 2008, Fujitsu Services Limited's (Fujitsu) contract as the prime contractor in the National Health Service (NHS) initiative to automate clinical processes and digitize medical records in the Southern region of England was terminated by the NHS. This had the effect of automatically terminating our subcontract for the project. We continue to be in dispute with Fujitsu regarding Fujitsu's obligation to pay the amounts comprised of accounts receivable and contracts receivable related to that subcontract, and we are working with Fujitsu to resolve these issues based on processes provided for in the contract. Part of that process requires final resolution of disputes between Fujitsu and the NHS regarding the contract termination. As of July 4, 2015, it remains unlikely that our matter with Fujitsu will be resolved in the next 12 months. Therefore, these receivables have been classified as long-term and represent less than the majority of other long-term assets at July 4, 2015 and January 3, 2015. While the ultimate collectability of the receivables pursuant to this process is uncertain, we believe that we have valid and equitable grounds for recovery of such amounts and that collection of recorded amounts is probable. Nevertheless, it is reasonably possible that our estimates regarding collectability of such amounts might materially change in the near term, considering that we do not have complete knowledge of the status of the proceedings between Fujitsu and NHS and their effect on our claim.

During the first six months of 2015 and 2014, we received total client cash collections of \$2.1 billion and \$1.7 billion, respectively.

(6) Income Taxes

We determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.

Our effective tax rate was 33.1% and 33.8% for the first six months of 2015 and 2014, respectively. The decrease in the 2015 effective tax rate results principally from the favorability of net discrete items recorded in 2015 as compared to 2014.

Table of Contents

(7) Earnings Per Share

A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows:

(In thousands, except per share data)	Three Months Ended			2014		
	2015					
	Earnings	Shares	Per-Share	Earnings	Shares	Per-Share
	(Numerator)	(Denominator)	Amount	(Numerator)	(Denominator)	Amount
Basic earnings per share:						
Income available to common shareholders	\$ 115,038	344,431	\$0.33	\$ 129,033	341,788	\$0.38
Effect of dilutive securities:						
Stock options and non-vested shares	—	8,019		—	8,006	
Diluted earnings per share:						
Income available to common shareholders including assumed conversions	\$ 115,038	352,450	\$0.33	\$ 129,033	349,794	\$0.37

For the three months ended July 4, 2015 and June 28, 2014, options to purchase 2.8 million and 5.9 million shares of common stock at per share prices ranging from \$54.09 to \$73.40 and \$38.66 to \$60.37, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

(In thousands, except per share data)	Six Months Ended			2014		
	2015					
	Earnings	Shares	Per-Share	Earnings	Shares	Per-Share
	(Numerator)	(Denominator)	Amount	(Numerator)	(Denominator)	Amount
Basic earnings per share:						
Income available to common shareholders	\$ 225,972	343,880	\$0.66	\$ 248,559	342,787	\$0.73
Effect of dilutive securities:						
Stock options and non-vested shares	—	8,282		—	8,262	
Diluted earnings per share:						
Income available to common shareholders including assumed conversions	\$ 225,972	352,162	\$0.64	\$ 248,559	351,049	\$0.71

For the six months ended July 4, 2015 and June 28, 2014, options to purchase 1.9 million and 4.8 million shares of common stock at per share prices ranging from \$53.17 to \$73.40 and \$38.66 to \$60.37, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

Table of Contents

(8) Share-Based Compensation

Stock Options

Options activity for the six months ended July 4, 2015 was as follows:

(In thousands, except per share data)	Number of Shares	Weighted-Average Exercise Price	Aggregate Intrinsic Value	Weighted-Average Remaining Contractual Term (Yrs)
Outstanding at beginning of year	24,629	\$27.00		
Granted	3,154	68.22		
Exercised	(2,900)	14.20		
Forfeited and expired	(228)	47.51		
Outstanding as of July 4, 2015	24,655	33.59	\$862,290	6.30
Exercisable as of July 4, 2015	14,213	\$19.32	\$698,720	4.71

The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the six months ended July 4, 2015 were as follows:

Expected volatility (%)	27.4	%
Expected term (yrs)	7	
Risk-free rate (%)	1.8	%
Fair value per option	\$21.85	

As of July 4, 2015, there was \$170 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 3.58 years.

Non-vested Shares

Non-vested share activity for the six months ended July 4, 2015 was as follows:

(In thousands, except per share data)	Number of Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of year	506	\$ 46.21
Granted	293	69.21
Vested	(172)	44.78
Forfeited	(55)	42.72
Outstanding as of July 4, 2015	572	\$ 58.82

As of July 4, 2015, there was \$23 million of total unrecognized compensation cost related to non-vested share awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.89 years.

Table of Contents

The following table presents total compensation expense recognized with respect to stock options, non-vested shares and our associate stock purchase plan:

(In thousands)	Three Months Ended		Six Months Ended	
	2015	2014	2015	2014
Stock option and non-vested share compensation expense	\$19,290	\$14,620	\$34,451	\$28,269
Associate stock purchase plan expense	1,365	1,094	2,753	2,377
Amounts capitalized in software development costs, net of amortization	(208)	(510)	(300)	(674)
Amounts charged against earnings, before income tax benefit	\$20,447	\$15,204	\$36,904	\$29,972
Amount of related income tax benefit recognized in earnings	\$6,664	\$5,336	\$12,197	\$10,520

(9) Long-Term Debt and Capital Lease Obligations

The following is a summary of indebtedness outstanding:

(In thousands)	July 4, 2015	January 3, 2015
Note agreement, 5.54% Senior Notes	\$14,471	\$14,233
Capital lease obligations	500,000	—
	109,055	116,095
Debt and capital lease obligations	623,526	130,328
Less: debt issuance costs	(766)	—
Debt and capital lease obligations, net	622,760	130,328
Less: current portion	(55,448)	(67,460)
Long-term debt and capital lease obligations	\$567,312	\$62,868

In January 2015, we issued \$500 million aggregate principal amount of unsecured Senior Notes ("Notes"), pursuant to a Master Note Purchase Agreement dated December 4, 2014. The issuance consisted of \$225 million of 3.18% Series 2015-A Notes due February 15, 2022, \$200 million of 3.58% Series 2015-B Notes due February 14, 2025, and \$75 million in floating rate Series 2015-C Notes due February 15, 2022. Interest is payable semiannually on February 15th and August 15th in each year, commencing on August 15, 2015, for the Series 2015-A Notes and Series 2015-B Notes. The Series 2015-C Notes will accrue interest at a floating rate equal to the Adjusted LIBOR Rate (as defined in the Master Note Purchase Agreement), payable quarterly on February 15th, May 15th, August 15th and November 15th in each year, commencing on May 15, 2015. As of July 4, 2015, the interest rate was 1.28% for the current interest period based on the three-month floating LIBOR rate. The debt issuance costs in the table above relate to the issuance of these Notes. The Master Note Purchase Agreement contains certain leverage and interest coverage ratio covenants and provides certain restrictions on our ability to borrow, incur liens, sell assets, and other customary terms. Proceeds from the Notes are available for general corporate purposes.

As of July 4, 2015, we were in compliance with all debt covenants.

(10) Contingencies

We accrue estimates for resolution of any legal and other contingencies when losses are probable and estimable, in accordance with ASC 450, Contingencies.

The terms of our software license agreements with our clients generally provide for a limited indemnification of such clients against losses, expenses and liabilities arising from third party claims based on alleged infringement by our solutions of an intellectual property right of such third party. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include a right to replace or modify an infringing solution. To date, we have not had to reimburse any of our clients for any judgments or settlements to third parties related to these indemnification provisions pertaining to intellectual property infringement claims. For several reasons, including the lack of prior indemnification claims and the lack of a monetary liability limit for certain infringement cases under the terms of the corresponding agreements with

Table of Contents

our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions.

In addition to commitments and obligations in the ordinary course of business, we are subject to various legal proceedings and claims, including for example, employment disputes and litigation alleging solution defects, personal injury, intellectual property infringement, violations of law and breaches of contract and warranties. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

(11) Segment Reporting

We have two operating segments, Domestic and Global. Revenues are derived primarily from the sale of clinical, financial and administrative information systems and solutions. The cost of revenues includes the cost of third party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, acquisition costs and related adjustments, share-based compensation expense, and certain amortization and depreciation. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis.

In connection with our acquisition of the Cerner Health Services business, we commenced an evaluation of our methodology for allocating operating expenses to our reportable segments. Effective for our first quarter of 2015, certain expenses historically reported in "Other" have been allocated to the geographic segments. This new allocation reflects the manner in which the business is now managed, subsequent to the acquisition. While this reporting change did not impact our consolidated results, the segment data has been recast to be consistent for all periods presented.

Table of Contents

The following table presents a summary of our operating segments and other expense for the three and six months ended July 4, 2015 and June 28, 2014:

(In thousands)	Domestic	Global	Other	Total
Three Months Ended 2015				
Revenues	\$994,746	\$131,251	\$—	\$1,125,997
Cost of revenues	168,189	24,133	—	192,322
Operating expenses	393,305	59,827	308,807	761,939
Total costs and expenses	561,494	83,960	308,807	954,261
Operating earnings (loss) (In thousands)	\$433,252	\$47,291	\$(308,807)	\$171,736
	Domestic	Global	Other	Total
Three Months Ended 2014				
Revenues	\$766,763	\$84,999	\$—	\$851,762
Cost of revenues	147,776	14,593	—	162,369
Operating expenses	283,609	47,849	166,302	497,760
Total costs and expenses	431,385	62,442	166,302	660,129
Operating earnings (loss) (In thousands)	\$335,378	\$22,557	\$(166,302)	\$191,633
	Domestic	Global	Other	Total
Six Months Ended 2015				
Revenues	\$1,865,253	\$256,833	\$—	\$2,122,086
Cost of revenues	310,906	50,076	—	360,982
Operating expenses	754,391	110,398	557,667	1,422,456
Total costs and expenses	1,065,297	160,474	557,667	1,783,438
Operating earnings (loss) (In thousands)	\$799,956	\$96,359	\$(557,667)	\$338,648
	Domestic	Global	Other	Total
Six Months Ended 2014				
Revenues	\$1,464,467	\$172,056	\$—	\$1,636,523
Cost of revenues	263,121	28,347	—	291,468
Operating expenses	557,599	92,918	324,902	975,419
Total costs and expenses	820,720	121,265	324,902	1,266,887
Operating earnings (loss)	\$643,747	\$50,791	\$(324,902)	\$369,636

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management Discussion and Analysis (MD&A) is intended to help the reader understand the results of operations and financial condition of Cerner Corporation (Cerner, the Company, we, us or our). This MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes to the financial statements (Notes) found above.

The 2015 and 2014 second quarters ended on July 4, 2015 and June 28, 2014, respectively. All references to years in this MD&A represent the respective three or six months ended on such dates, unless otherwise noted.

Except for the historical information and discussions contained herein, statements contained in this quarterly report on Form 10-Q may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended (the Exchange Act). Forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. These statements can often be identified by the use of forward-looking terminology, such as "could," "should," "will," "intends," "continue," "believe," "may," "expect," "anticipate," "goal," "forecast," "plan," or "estimate" or the negative of these words, variations thereof or similar expressions. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including without limitation: the possibility of product-related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; material adverse resolution of legal proceedings; risks associated with our non-U.S. operations; risks associated with our ability to effectively hedge exposure to fluctuations in foreign currency exchange rates; the potential for tax legislation initiatives that could adversely affect our tax position and/or challenges to our tax positions in the United States and non-U.S. countries; risks associated with our recruitment and retention of key personnel; risks related to our dependence on third party suppliers; risks inherent with business acquisitions and combinations and the integration thereof, such as difficulties and operational and financial risks associated with integrating Cerner and the Siemens Health Services business acquired from Siemens AG (the "Acquisition"); risks related to disruption of management time from ongoing business operations due to the integration of the business acquired in the Acquisition; failure to realize the synergies and other benefits expected from the Acquisition; risk that the assets and business acquired in the Acquisition may not continue to be commercially successful; the effect of the Acquisition on the ability of Cerner to retain customers and retain and hire key personnel and maintain relationships with key suppliers; litigation, claims or post-closing disputes relating to the Acquisition or the acquired assets and business; the potential for losses resulting from asset impairment charges; risks associated with volatility and disruption resulting from global economic conditions; managing growth in the new markets in which we offer solutions, health care devices and services; incurring significant additional expenses relating to the integration of the Siemens Health Services business into Cerner; compliance with restrictive covenants in our debt agreements, which may restrict our flexibility to operate our business; changing political, economic, regulatory and judicial influences; government regulation; significant competition and market changes; variations in our quarterly operating results; potential inconsistencies in our sales forecasts compared to actual sales; volatility in the trading price of our common stock and the timing and volume of market activity; our directors' authority to issue preferred stock and the anti-takeover provisions in our corporate governance documents; and, other risks, uncertainties and factors discussed elsewhere in this Form 10-Q, in our other filings with the Securities and Exchange Commission, including those under the caption "Risk Factors" in our latest annual report on Form 10-K, or in materials incorporated herein or therein by reference. Forward-looking statements are not guarantees of future performance or results. The reader should not place undue reliance on forward-looking statements since the statements speak only as of the date they are made. We undertake no obligation to update or revise forward-looking statements to reflect changed

assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.

Management Overview

Our revenues are primarily derived by selling, implementing and supporting software solutions, clinical content, hardware, devices and services that give health care providers secure access to clinical, administrative and financial data in real or near-real time, helping them improve quality, safety and efficiency in the delivery of health care.

Our fundamental strategic focus is the creation of organic growth by investing in research and development (R&D) to create solutions and services for the health care industry. This strategy has driven strong growth over the long-term, as reflected in five- and ten-year compound annual revenue growth rates of 14% or more. This growth has also created an important strategic footprint in health care, with Cerner[®] solutions in more than 18,000 facilities worldwide, including hospitals, physician

Table of Contents

practices, laboratories, ambulatory centers, behavioral health centers, cardiac facilities, radiology clinics, surgery centers, extended care facilities, retail pharmacies, and employer sites. Selling additional solutions back into this client base is an important element of our future revenue growth. We are also focused on driving growth through market share expansion by strategically aligning with health care providers that have not yet selected a supplier and by displacing competitors in health care settings that are looking to replace their current supplier. We may also supplement organic growth with acquisitions.

We expect to drive growth through solutions and services that reflect our ongoing ability to innovate and expand our reach into health care. Examples of these include our CareAware[®] health care device architecture and devices, Cerner ITWorksSM services, revenue cycle solutions and services, and population health solutions and services. Finally, we believe there is significant opportunity for growth outside of the United States, with many non-U.S. markets focused on health care information technology as part of their strategy to improve the quality and lower the cost of health care.

Beyond our strategy for driving revenue growth, we are also focused on earnings growth. Similar to our history of growing revenue, our net earnings have increased at compound annual rates of 20% or more over the most recent five- and ten-year periods. We expect to drive continued earnings growth through ongoing revenue growth coupled with margin expansion, which we expect to achieve through efficiencies in our implementation and operational processes and by leveraging R&D investments and controlling general and administrative expenses.

We are also focused on continuing to deliver strong levels of cash flow, which we expect to accomplish by continuing to grow earnings and prudently managing capital expenditures.

Siemens Health Services

On February 2, 2015, we acquired substantially all of the assets, and assumed certain liabilities of Siemens Health Services, as further described in Note (2) of the notes to condensed consolidated financial statements. The acquired business (now referred to as "Cerner Health Services") offers a portfolio of enterprise-level clinical and financial health care information technology solutions, as well as departmental, connectivity, population health, and care coordination solutions globally. Solutions are offered on the Soarian, Invision, and i.s.h.med platforms, among others. Cerner Health Services also offers a range of complementary services including support, hosting, managed services, implementation services, and strategic consulting.

We believe the acquisition enhances our organic growth opportunities as it provides us a larger base into which we can sell our combined portfolio of solutions and services. The acquisition also augments our non-U.S. footprint and growth opportunities, increases our scale for R&D investment, and adds over 5,000 highly-skilled associates that will enhance our capabilities.

The addition of this business has a significant impact on the comparability of our condensed consolidated financial statements as of and for the three and six months ended July 4, 2015, in relation to the comparative periods presented herein.

Results Overview

The Company delivered strong levels of bookings, revenues and earnings in the second quarter of 2015.

New business bookings revenue, which reflects the value of executed contracts for software, hardware, professional services and managed services, was \$1.3 billion in the second quarter of 2015, which is an increase of 20% compared to \$1.1 billion in the second quarter of 2014.

Revenues for the second quarter of 2015 increased 32% to \$1.1 billion compared to \$852 million in the second quarter of 2014. Second quarter 2015 revenues include approximately \$260 million attributable to the acquired Cerner Health

Services business. The remaining year-over-year increase in revenue reflects ongoing demand for Cerner's core solutions and services driven by our clients' needs to keep up with regulatory requirements, contributions from Cerner ITWorks and revenue cycle solutions and services, and attaining new clients.

Second quarter 2015 net earnings decreased 11% to \$115 million compared to \$129 million in the second quarter of 2014. Diluted earnings per share decreased 11% to \$0.33 compared to \$0.37 in the second quarter of 2014. Disclosure of the earnings contribution from the Cerner Health Services business is not practicable, as we have already integrated operations in many areas. The overall decrease in net earnings and diluted earnings per share was primarily a result of elevated operating expenses associated with our voluntary separation plan, and the acquisition and integration of the Cerner Health Services business, as discussed further below.

Table of Contents

Second quarter 2015 and 2014 net earnings and diluted earnings per share reflect the impact of share-based compensation expense. The effect of these expenses reduced the second quarter 2015 net earnings and diluted earnings per share by \$14 million and \$0.04, respectively, and the second quarter 2014 net earnings and diluted earnings per share by \$10 million and \$0.03, respectively.

Second quarter 2015 net earnings and diluted earnings per share also reflect the impact of amortization of acquisition-related intangibles and acquisition costs and related adjustments, both associated with our acquisition and integration of the Cerner Health Services business, as well as costs related to the voluntary separation plan, as further described in Note (1) of the notes to condensed consolidated financial statements. Amortization of acquisition-related intangibles related to the Cerner Health Services business reduced net earnings and diluted earnings per share by \$14 million and \$0.04, respectively. Acquisition costs and related adjustments related to the Cerner Health Services business reduced net earnings and diluted earnings per share by \$6 million and \$0.01, respectively. Costs related to the voluntary separation plan reduced net earnings and diluted earnings per share by \$28 million and \$0.08, respectively.

We had cash collections of receivables of \$1.1 billion in the second quarter of 2015 compared to \$844 million in the second quarter of 2014. Days sales outstanding was 81 days for the second quarter of 2015 compared to 79 days for the first quarter of 2015 and 66 days for the second quarter of 2014. Operating cash flows for the second quarter of 2015 were \$109 million compared to \$248 million in the second quarter of 2014.

Table of Contents

Results of Operations

Three Months Ended July 4, 2015 Compared to Three Months Ended June 28, 2014

The following table presents a summary of the operating information for the second quarters of 2015 and 2014:

(In thousands)	2015	% of Revenue		2014	% of Revenue	% Change	
Revenues							
System sales	\$315,109	28 %		\$234,563	28 %	34 %	
Support and maintenance	254,663	23 %		175,274	21 %	45 %	
Services	538,164	48 %		412,893	48 %	30 %	
Reimbursed travel	18,061	2 %		29,032	3 %	(38) %	
Total revenues	1,125,997	100 %		851,762	100 %	32 %	
Costs of revenue							
Costs of revenue	192,322	17 %		162,369	19 %	18 %	
Total margin	933,675	83 %		689,393	81 %	35 %	
Operating expenses							
Sales and client service	463,435	41 %		343,234	40 %	35 %	
Software development	138,451	12 %		97,326	11 %	42 %	
General and administrative	135,545	12 %		53,971	6 %	151 %	
Amortization of acquisition-related intangibles	24,508	2 %		3,229	— %	659 %	
Total operating expenses	761,939	68 %		497,760	58 %	53 %	
Total costs and expenses	954,261	85 %		660,129	78 %	45 %	
Operating earnings	171,736	15 %		191,633	22 %	(10) %	
Other income (expense), net	(1,079)			2,737			
Income taxes	(55,619)			(65,337)			
Net earnings	\$115,038			\$129,033		(11) %	

Revenues & Backlog

Revenues increased 32% to \$1.1 billion in the second quarter of 2015, as compared to \$852 million in the second quarter of 2014.

System sales, which include revenues from the sale of licensed software (including perpetual license sales and software as a service), technology resale (hardware, devices, and sublicensed software), deployment period licensed software upgrade rights, installation fees, transaction processing and subscriptions, increased 34% to \$315 million in the second quarter of 2015 from \$235 million for the same period in 2014. The increase in system sales was primarily driven by contributions from the Cerner Health Services business.

Support and maintenance revenues increased 45% to \$255 million in the second quarter of 2015 compared to \$175 million during the same period in 2014. This increase was primarily attributable to contributions from the Cerner Health Services business.

Services revenue, which includes professional services, excluding installation, and managed services, increased 30% to \$538 million in the second quarter of 2015 from \$413 million for the same period in 2014. This increase was primarily driven by contributions from the Cerner Health Services business.

Revenue backlog, which reflects contracted revenue that has not yet been recognized as revenue, increased 37% to \$13.3 billion in the second quarter of 2015 compared to \$9.7 billion for the same period in 2014. This increase was driven by growth in new business bookings during the past four quarters, including continued strong levels of managed services, Cerner ITWorks and revenue cycle services bookings that typically have longer contract terms, coupled with contributions from the Cerner Health Services business.

Table of Contents

Costs of Revenue

Cost of revenues as a percentage of total revenues was 17% in the second quarter of 2015, compared to 19% in the same period of 2014. The lower cost of revenues as a percent of revenue was primarily driven by a lower mix of technology resale, which carries a higher cost of revenue, combined with the prior period quarter including a higher amount of third party resources being utilized for support and services related to a significant amount of systems going live during that quarter.

Cost of revenues includes the cost of reimbursed travel expense, sales commissions, third party consulting services and subscription content and computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Such costs, as a percent of revenues, typically have varied as the mix of revenue (software, hardware, devices, maintenance, support, services and reimbursed travel) carrying different margin rates changes from period to period. Cost of revenues does not include the costs of our client service personnel who are responsible for delivering our service offerings. Such costs are included in sales and client service expense.

Operating Expenses

Total operating expenses increased 53% to \$762 million in the second quarter of 2015, compared with \$498 million in the second quarter of 2014.

Sales and client service expenses as a percent of total revenues were 41% in the second quarter of 2015, compared to 40% in the same period of 2014. These expenses increased 35% to \$463 million in the second quarter of 2015, from \$343 million in the same period of 2014. Sales and client service expenses include salaries and benefits of sales, marketing, support, and services personnel, depreciation and other expenses associated with our managed services business, communications expenses, unreimbursed travel expenses, expense for share-based payments, and trade show and advertising costs. The increase was primarily driven by addition of the Cerner Health Services business. Software development expenses as a percent of revenue were 12% in the second quarter of 2015, compared to 11% in the same period of 2014. Expenditures for software development reflect ongoing development and enhancement of the Cerner Millennium[®] and HealthIntentSM platforms, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. The second quarter of 2015 also includes expenditures related to Cerner Health Services solutions. A summary of our total software development expense in the second quarters of 2015 and 2014 is as follows:

(In thousands)	Three Months Ended	
	2015	2014
Software development costs	\$ 178,630	\$ 114,511
Capitalized software costs	(69,116)	(41,225)
Capitalized costs related to share-based payments	(681)	(897)
Amortization of capitalized software costs	29,618	24,937
Total software development expense	\$ 138,451	\$ 97,326

General and administrative expenses as a percent of total revenues were 12% in the second quarter of 2015, compared to 6% in the same period of 2014. These expenses increased 151% to \$136 million in 2015, from \$54 million for the same period in 2014. General and administrative expenses include salaries and benefits for corporate, financial and administrative staffs, utilities, communications expenses, professional fees, depreciation and amortization, transaction gains or losses on foreign currency, expense for share-based payments, acquisition costs and related adjustments. The increase in general and administrative expenses as a percent of total revenues was primarily driven by expenses related to our voluntary separation plan and expenses associated with the acquisition and integration of the Cerner Health Services business. Specifically, the second quarter of 2015 includes costs associated with the voluntary separation plan and acquisition costs and related adjustments of \$42 million and \$9 million, respectively. We expect costs related to our voluntary separation plan and acquisition costs and related adjustments to significantly decline in

future periods. Refer to Note (1) of the notes to condensed consolidated financial statements for further detail regarding the voluntary separation plan.

Amortization of acquisition-related intangibles increased 659% to \$25 million in the second quarter of 2015, from \$3 million for the same period in 2014. Amortization of acquisition-related intangibles includes the amortization of customer relationships, acquired technology, trade names, and non-compete agreements recorded in connection

21

Table of Contents

with our business acquisitions. The increase in amortization of acquisition-related intangibles was driven by the acquisition of the Cerner Health Services business in the first quarter of 2015. Refer to Note (2) of the notes to condensed consolidated financial statements for further detail regarding intangible assets recorded in connection with our acquisition of the Cerner Health Services business.

Non-Operating Items

Other income (expense) was \$(1) million in the second quarter of 2015 and \$3 million in the same period of 2014. This decline is primarily due to increased interest expense as a result of the issuance of Notes in January 2015, as further discussed in Note (9) of the notes to condensed consolidated financial statements.

- Our effective tax rate was 32.6% for the second quarter of 2015 and 33.6% for the second quarter of 2014. The decrease in 2015 results principally from the favorability of net discrete items recorded in the second quarter of 2015 as compared to the second quarter of 2014.

Operations by Segment

We have two operating segments: Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The Global segment includes revenue contributions and expenditures linked to business activity in Aruba, Australia, Austria, Belgium, Brazil, Canada, Cayman Islands, Chile, Denmark, Egypt, England, Finland, France, Germany, Guam, India, Ireland, Israel, Luxembourg, Malaysia, Mexico, Netherlands, Norway, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland and the United Arab Emirates. Refer to Note (11) of the notes to condensed consolidated financial statements for further information regarding our reportable segments.

The following table presents a summary of the operating segment information for the second quarters of 2015 and 2014:

(In thousands)	2015	% of Revenue	2014	% of Revenue	% Change
Domestic Segment Revenues	\$994,746	100%	\$766,763	100%	30%
Costs of revenue	168,189	17%	147,776	19%	14%
Operating expenses	393,305	40%	283,609	37%	39%
Total costs and expenses	561,494	56%	431,385	56%	30%
Domestic operating earnings	433,252	44%	335,378	44%	29%
Global Segment Revenues	131,251	100%	84,999	100%	54%
Costs of revenue	24,133	18%	14,593	17%	65%
Operating expenses	59,827	46%	47,849	56%	25%
Total costs and expenses	83,960	64%	62,442	73%	34%
Global operating earnings	47,291	36%	22,557	27%	110%
Other, net	(308,807)		(166,302)		86%

Edgar Filing: Time Inc. - Form SC TO-T/A

Consolidated operating earnings	\$171,736	\$191,633	(10)%
---------------------------------	-----------	-----------	-------

Domestic Segment

Revenues increased 30% to \$995 million in the second quarter of 2015 from \$767 million in the same period of 2014. The increase was primarily driven by contributions from the Cerner Health Services business.

Cost of revenues was 17% of revenues in the second quarter of 2015, compared to 19% of revenues in the same period of 2014. The lower cost of revenues as a percent of revenue was primarily driven by a lower mix of technology resale, which carries a higher cost of revenue, combined with the prior period quarter including a higher amount of

Table of Contents

third party resources being utilized for support and services related to a significant amount of systems going live during that quarter.

Operating expenses were 40% of revenues in the second quarter of 2015, compared to 37% in the same period of 2014. The increase as a percent of revenues was primarily driven by the addition of the Cerner Health Services business.

Global Segment

Revenues increased 54% to \$131 million in the second quarter of 2015 from \$85 million in the same period of 2014. This increase was driven by contributions from the Cerner Health Services business.

Cost of revenues was 18% of revenues in the second quarter of 2015, compared to 17% of revenues in the same period of 2014. The higher cost of revenues in 2015 was primarily driven by a higher amount of third party resources utilized for support and services.

Operating expenses were at 46% of revenues in the second quarter of 2015, compared to 56% of revenues in the same period of 2014. The lower operating expenses as a percent of revenue in 2015 includes \$3 million of lower bad debt expense and a higher amount of third party resources utilized for support and services, as discussed above.

Other, net

Operating results not attributed to an operating segment include expenses, such as software development, general and administrative expenses, acquisition costs and related adjustments, share-based compensation expense, and certain amortization and depreciation. These expenses increased 86% to \$309 million in the second quarter of 2015 from \$166 million in the same period of 2014. This increase is primarily due to the addition of corporate and development personnel from our acquisition of the Cerner Health Services business. Additionally, the second quarter of 2015 includes costs related to our voluntary separation plan, amortization of acquisition-related intangibles associated with our Cerner Health Services business, and acquisition costs and related adjustments of \$42 million, \$21 million and \$9 million, respectively.

Table of Contents

Six Months Ended July 4, 2015 Compared to Six Months Ended June 28, 2014

The following table presents a summary of the operating information for the first six months of 2015 and 2014:

(In thousands)	2015	% of Revenue	2014	% of Revenue	% Change
Revenues					
System sales	\$574,678	27 %	\$441,250	27 %	30 %
Support and maintenance	483,428	23 %	350,204	21 %	38 %
Services	1,027,769	48 %	795,392	49 %	29 %
Reimbursed travel	36,211	2 %	49,677	3 %	(27) %
Total revenues	2,122,086	100 %	1,636,523	100 %	30 %
Costs of revenue					
Costs of revenue	360,982	17 %	291,468	18 %	24 %
Total margin	1,761,104	83 %	1,345,055	82 %	31 %
Operating expenses					
Sales and client service	883,617	42 %	674,135	41 %	31 %
Software development	265,722	13 %	188,871	12 %	41 %
General and administrative	230,356	11 %	105,957	6 %	117 %
Amortization of acquisition-related intangibles	42,761	2 %	6,456	— %	562 %
Total operating expenses	1,422,456	67 %	975,419	60 %	46 %
Total costs and expenses	1,783,438	84 %	1,266,887	77 %	41 %
Operating earnings	338,648	16 %	369,636	23 %	(8) %
Other income (expense), net	(871)		5,727		
Income taxes	(111,805)		(126,804)		
Net earnings	\$225,972		\$248,559		(9) %

Revenues

Revenues increased 30% to \$2.1 billion in the first six months of 2015, as compared to \$1.6 billion in the first six months of 2014.

System sales increased 30% to \$575 million in the first six months of 2015 from \$441 million for the same period in 2014. The increase in system sales was primarily driven by contributions from the Cerner Health Services business. Support and maintenance revenues increased 38% to \$483 million in the first six months of 2015 compared to \$350 million during the same period in 2014. This increase was primarily attributable to contributions from the Cerner Health Services business.

Services revenue increased 29% to \$1.0 billion in the first six months of 2015 from \$795 million for the same period in 2014. This increase was primarily driven by contributions from the Cerner Health Services business.

Costs of Revenue

Cost of revenues as a percentage of total revenues was 17% in the first six months of 2015, compared to 18% in the same period of 2014. The lower cost of revenues as a percent of revenue was driven by a lower mix of technology resale, which carries a higher cost of revenue, combined with 2014 including a higher amount of third party resources

being utilized for support and services related to a significant amount of systems going live during that period.

Operating Expenses

Total operating expenses increased 46% to \$1.4 billion in the first six months of 2015, compared with \$975 million in the same period of 2014.

Table of Contents

Sales and client service expenses as a percent of total revenues were 42% in the first six months of 2015, compared to 41% in the same period of 2014. These expenses increased 31% to \$884 million in the first six months of 2015, from \$674 million in the same period of 2014. The increase was primarily driven by the addition of the Cerner Health Services business.

Software development expenses as a percent of revenue were 13% in the first six months of 2015, compared to 12% in the same period of 2014. Expenditures for software development reflect ongoing development and enhancement of the Cerner Millennium and HealthIntent platforms, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. The first six months of 2015 also includes expenditures related to Cerner Health Services solutions. A summary of our total software development expense in the first six months of 2015 and 2014 is as follows:

(In thousands)	Six Months Ended	
	2015	2014
Software development costs	\$339,879	\$225,499
Capitalized software costs	(131,640)	(85,209)
Capitalized costs related to share-based payments	(1,224)	(1,457)
Amortization of capitalized software costs	58,707	50,038
Total software development expense	\$265,722	\$188,871

General and administrative expenses as a percent of total revenues were 11% in the first six months of 2015, compared to 6% in the same period of 2014. These expenses increased 117% to \$230 million in 2015, from \$106 million for the same period in 2014. The increase in general and administrative expenses as a percent of total revenues was primarily driven by expenses related to our voluntary separation plan and expenses associated with the acquisition and integration of the Cerner Health Services business. Specifically, the six months ended July 4, 2015 includes costs associated with the voluntary separation plan and acquisition costs and related adjustments (includes acquisition and employee separation costs) of \$42 million and \$34 million, respectively. We expect costs related to our voluntary separation plan and acquisition costs and related adjustments to significantly decline in future periods. Refer to Note (1) of the notes to condensed consolidated financial statements for further detail regarding the voluntary separation plan.

Amortization of acquisition-related intangibles increased 562% to \$43 million in 2015, from \$6 million for the same period in 2014. The increase in amortization of acquisition-related intangibles was primarily driven by the acquisition of the Cerner Health Services business in the first quarter of 2015. Refer to Note (2) of the notes to condensed consolidated financial statements for further detail regarding intangible assets recorded in connection with our acquisition of the Cerner Health Services business.

Non-Operating Items

Other income (expense) decreased to \$(1) million in the first six months of 2015 from \$6 million in the same period of 2014. The decline is primarily due to increased interest expense as a result of the issuance of Notes in January 2015, as further discussed in Note (9) of the notes to condensed consolidated financial statements.

Our effective tax rate was 33.1% for the first six months of 2015 and 33.8% for the first six months of 2014. The decrease in 2015 results principally from the favorability of net discrete items recorded in 2015 as compared to 2014.

Table of Contents

Operations by Segment

The following table presents a summary of the operating segment information for the first six months of 2015 and 2014:

(In thousands)	2015	% of Revenue	2014	% of Revenue	% Change
Domestic Segment Revenues	\$1,865,253	100%	\$1,464,467	100%	27%
Costs of revenue	310,906	17%	263,121	18%	18%
Operating expenses	754,391	40%	557,599	38%	35%
Total costs and expenses	1,065,297	57%	820,720	56%	30%
Domestic operating earnings	799,956	43%	643,747	44%	24%
Global Segment Revenues	256,833	100%	172,056	100%	49%
Costs of revenue	50,076	19%	28,347	16%	77%
Operating expenses	110,398	43%	92,918	54%	19%
Total costs and expenses	160,474	62%	121,265	70%	32%
Global operating earnings	96,359	38%	50,791	30%	90%
Other, net	(557,667)		(324,902)		72%
Consolidated operating earnings	\$338,648		\$369,636		(8)%

Domestic Segment

Revenues increased 27% to \$1.9 billion in the first six months of 2015 from \$1.5 billion in the first six months of 2014. This increase was primarily driven by contributions from the Cerner Health Services business.

Cost of revenues was 17% of revenues in the first six months of 2015, compared to 18% of revenues in the same period of 2014. The lower cost of revenues as a percent of revenue was primarily driven by a lower mix of technology resale, which carries a higher cost of revenue, combined with 2014 including a higher amount of third party resources being utilized for support and services related to a significant amount of systems going live during that period.

Operating expenses were 40% of revenues in the first six months of 2015, compared to 38% in the same period of 2014. The increase as a percent of revenues was primarily driven by the addition of the Cerner Health Services business.

Global Segment

Revenues increased 49% to \$257 million in the first six months of 2015 from \$172 million in the same period of 2014. This increase was primarily driven by contributions from the Cerner Health Services business.

Cost of revenues was 19% of revenues in the first six months of 2015, compared to 16% of revenues in the same period of 2014. The higher cost of revenues in 2015 was primarily driven by a higher amount of third party resources utilized for support and services.

Operating expenses were 43% of revenues in the first six months of 2015, compared to 54% of revenues in the same period of 2014. The lower operating expenses as a percent of revenue in 2015 includes \$4 million of lower bad debt expense and a higher amount of third party resources utilized for support and services, as discussed above.

Other, net

These expenses increased 72% to \$558 million in the first six months of 2015 from \$325 million in the same period of 2014. This increase was primarily due to the addition of corporate and development personnel from our acquisition of the Cerner Health Services business. Additionally, the first six months of 2015 includes costs related to our voluntary separation plan, amortization of acquisition-related intangibles associated with our Cerner Health Services business, and acquisition costs and related adjustments (includes acquisition and employee separation costs) of \$42 million, \$36 million and \$34 million, respectively.

Table of Contents

Liquidity and Capital Resources

Our liquidity is influenced by many factors, including the amount and timing of our revenues, our cash collections from our clients and the amount we invest in software development, acquisitions and capital expenditures.

Our principal sources of liquidity are our cash and cash equivalents, which primarily consist of money market funds and time deposits with original maturities of less than 90 days, and short-term investments. At July 4, 2015, we had cash and cash equivalents of \$294 million and short-term investments of \$264 million, as compared to cash and cash equivalents of \$635 million and short-term investments of \$786 million at January 3, 2015. We utilized a large amount of cash and investments to fund our acquisition of the Cerner Health Services business in February 2015. The non-U.S. subsidiaries for which we have elected to indefinitely reinvest earnings outside of the U.S. held approximately 24% of our aggregate cash, cash equivalents and short-term investments at July 4, 2015. As part of our current business strategy, we plan to indefinitely reinvest the earnings of these foreign operations; however, should the earnings of these foreign operations be repatriated, we would accrue and pay tax on such earnings, which may be material.

Additionally, we maintain a \$100 million multi-year revolving credit facility, which expires in February 2017. The facility provides an unsecured revolving line of credit for working capital purposes, along with a letter of credit facility. As of July 4, 2015, we had no outstanding borrowings under this agreement; however, we had \$17 million of outstanding letters of credit, which reduced our available borrowing capacity to \$83 million.

We believe that our present cash position, together with cash generated from operations, short-term investments and, if necessary, our available line of credit, will be sufficient to meet anticipated cash requirements during 2015.

The following table summarizes our cash flows in the first six months of 2015 and 2014:

(In thousands)	Six Months Ended	
	2015	2014
Cash flows from operating activities	\$322,911	\$404,058
Cash flows from investing activities	(1,230,780)	(161,939)
Cash flows from financing activities	573,104	(131,440)
Effect of exchange rate changes on cash	(6,459)	2,204
Total change in cash and cash equivalents	(341,224)	112,883
Cash and cash equivalents at beginning of period	635,203	202,377
Cash and cash equivalents at end of period	\$293,979	\$315,260
Free cash flow (non-GAAP)	\$22,913	\$185,395

Cash from Operating Activities

(In thousands)	Six Months Ended	
	2015	2014
Cash collections from clients	\$2,061,276	\$1,711,507
Cash paid to employees and suppliers and other	(1,674,522)	(1,198,457)
Cash paid for interest	(2,478)	(2,908)
Cash paid for taxes, net of refunds	(61,365)	(106,084)
Total cash from operations	\$322,911	\$404,058

Cash flow from operations decreased \$81 million in the first six months of 2015 when compared to the same period of 2014 due primarily to the increase in cash used to fund working capital requirements, along with payments in

connection with our voluntary separation program, as further described in Note (1) of the notes to condensed consolidated financial statements. Disclosure of the operating cash flow contribution from the Cerner Health Services business is not practicable, as we have already integrated operations in many areas. During the first six months of 2015 and 2014, we received total client cash collections of \$2.1 billion and \$1.7 billion, respectively. Days sales outstanding was 81 days in the second quarter of 2015, compared to 79 days in the first quarter of 2015 and 66 days in the second quarter of 2014. Revenues provided under support

27

Table of Contents

and maintenance agreements represent recurring cash flows. We expect these revenues to continue to grow as the base of installed systems grows.

Cash from Investing Activities

(In thousands)	Six Months Ended	
	2015	2014
Capital purchases	\$ (167,134)	\$ (131,997)
Capitalized software development costs	(132,864)	(86,666)
Sales and maturities of investments, net of purchases	448,127	71,390
Purchases of other intangibles	(6,895)	(7,190)
Acquisition of businesses	(1,372,014)	(7,476)
Total cash flows from investing activities	\$ (1,230,780)	\$ (161,939)

Cash flows from investing activities consist primarily of capital spending, short-term investment, and acquisition activities.

Our capital spending in 2015 is driven by capitalized equipment purchases primarily to support growth in our CernerWorksSM managed services business, investments in a cloud infrastructure to support cloud-based solutions, building and improvement purchases to support our facilities requirements and capitalized spending to support our ongoing software development initiatives. Capital spending in 2015 is expected to remain higher than 2014 comparable periods, as we continue our current capital and software development initiatives, fund equipment purchases and software development initiatives associated with our Cerner Health Services business, and fund construction on our Trails Campus (office space development located in Kansas City, Missouri).

Short-term investment activity historically consists of the investment of cash generated by our business in excess of what is necessary to fund operations. The increase in net cash from investments in the first half of 2015, compared to the same period in 2014 is due to the use of proceeds from investment maturities to partially fund our acquisition of the Cerner Health Services business in February 2015. We expect subsequent periods in 2015 to reflect net purchases of investments, as we expect strong levels of cash flow.

On February 2, 2015, we acquired the Cerner Health Services business, as discussed above. Consideration for the acquisition was \$1.37 billion of cash, consisting of the \$1.3 billion agreed upon purchase price plus working capital adjustments. We used a combination of cash on hand and proceeds from the maturities of investments to fund the acquisition. Refer to Note (2) of the notes to condensed consolidated financial statements for further information regarding the acquisition.

Cash from Financing Activities

(In thousands)	Six Months Ended	
	2015	2014
Long-term debt issuance	\$ 500,000	\$—
Repayment of long-term debt and capital lease obligations	—	(69)
Cash from option exercises (including excess tax benefits)	84,907	34,817
Treasury stock purchases	—	(217,082)
Cash grants	—	48,000
Contingent consideration payments for acquisition of businesses	(11,012)	—
Other, net	(791)	2,894
Total cash flows from financing activities	\$ 573,104	\$ (131,440)

In January 2015, we issued \$500 million in aggregate principal amount of Notes. Proceeds from the Notes are available for general corporate purposes. Refer to Note (9) of the notes to consolidated financial statements for additional information regarding the Notes. We do not expect to issue additional long-term debt for the remainder of 2015.

Cash inflows from stock option exercises are dependent on a number of factors, including the price of our common stock, grant activity under our stock option and equity plans, and overall market volatility. We expect cash inflows from stock option

Table of Contents

exercises to continue throughout 2015 based on the number of exercisable options as of July 4, 2015 and our current stock price.

During the six months ended June 28, 2014, we purchased 4.1 million shares of our common stock for total consideration of \$217 million. At July 4, 2015, \$100 million remains available under the repurchase program authorized by our Board of Directors. We may continue to repurchase shares under this program in 2015, which will be dependent on a number of factors, including the price of our common stock.

In January 2014, we received \$48 million of cash grants from the Kansas Department of Commerce for project costs in connection with the construction of our Continuous Campus (owned office space in Kansas City, Kansas, which houses associates who manage and support our clients' IT systems).

During the six months ended July 4, 2015, we paid an aggregate of \$11 million of contingent consideration related to our acquisitions of InterMedHx, LLC and Kaufman & Keen, LLC (doing business as PureWellness).

Free Cash Flow

(In thousands)	Three Months Ended		Six Months Ended	
	2015	2014	2015	2014
Cash flows from operating activities (GAAP)	\$108,664	\$248,271	\$322,911	\$404,058
Capital purchases	(84,870)	(62,336)	(167,134)	(131,997)
Capitalized software development costs	(69,797)	(42,122)	(132,864)	(86,666)
Free cash flow (non-GAAP)	\$(46,003)	\$143,813	\$22,913	\$185,395

Free cash flow decreased \$162 million in the first six months of 2015 compared to the same period in 2014. This decrease is due to a decrease in cash flows from operations combined with higher levels of both capital spending to support our growth initiatives and facilities requirements and capitalized spending to support our ongoing software development initiatives. Free cash flow is a non-GAAP financial measure used by management along with GAAP results to analyze our earnings quality and overall cash generation of the business. We define free cash flow as cash flows from operations reduced by capital purchases and capitalized software development costs. The table above sets forth a reconciliation of free cash flow to cash flows from operating activities, which we believe to be the GAAP financial measure most directly comparable to free cash flow. The presentation of free cash flow is not meant to be considered in isolation, nor as a substitute for, or superior to, GAAP results, and investors should be aware that non-GAAP measures have inherent limitations and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Free cash flow may also be different from similar non-GAAP financial measures used by other companies and may not be comparable to similarly titled captions of other companies due to potential inconsistencies in the method of calculation. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review of our overall financial, operational and economic performance, because free cash flow takes into account the capital expenditures necessary to operate our business.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

No material changes.

Item 4. Controls and Procedures

The Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO) have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report on Form 10-Q (the Evaluation Date). They have concluded that, as of the Evaluation Date, these disclosure controls and procedures were effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities and would be disclosed on a timely basis. The CEO and CFO have concluded that the Company's disclosure controls and procedures are designed, and are effective, to give reasonable assurance that the information required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules and forms of the SEC. They have also concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act are accumulated and communicated to the Company's management to allow timely decisions regarding required disclosure.

On February 2, 2015, we acquired Siemens Health Services, as further described in Note (2) of the notes to condensed consolidated financial statements. We continue to integrate policies, processes, people, technology and operations for our combined operations, and we will continue to evaluate the impact of any related changes to internal control over financial reporting during the fiscal year. Except for any changes in internal controls related to the integration of the Siemens Health Services business into Cerner, there were no other changes in the Company's internal controls over financial reporting during the fiscal quarter ended July 4, 2015, that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

The Company's management, including its CEO and CFO, has concluded that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at that reasonable assurance level. However, the Company's management can provide no assurance that our disclosure controls and procedures or our internal control over financial reporting can prevent all errors and all fraud under all circumstances. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

Part II. Other Information

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) Issuer Purchases of Equity Securities

The table below provides information with respect to Common Stock purchases by the Company during the second fiscal quarter of 2015.

(In thousands, except share data)

Period	Total Number of Shares Purchased (a)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (b)
April 5, 2015 - May 2, 2015	154	\$71.81	—	\$100,000
May 3, 2015 - May 30, 2015	—	—	—	100,000
May 31, 2015 - July 4, 2015	52,983	67.81	—	100,000
Total	53,137	\$67.82	—	

(a) All of the shares of common stock in the table above were originally granted to employees as restricted stock pursuant to our 2011 Omnibus Equity Incentive Plan (the "Omnibus Plan"). The Omnibus Plan allows for the withholding of shares to satisfy the minimum tax obligations due upon the vesting of restricted stock. Pursuant to the Omnibus Plan, the shares reflected above were relinquished by employees in exchange for our agreement to pay federal and state withholding obligations resulting from the vesting of the Company's restricted stock.

(b) In May 2014, we announced that our Board of Directors approved an amendment to our existing stock repurchase program that was originally announced in December 2013, pursuant to which the maximum aggregate purchase price for all shares of our Common Stock authorized for repurchase under the program was increased by \$100 million to \$317 million, excluding transaction costs. As of July 4, 2015, \$100 million remained available for repurchase under the program. The program does not have an expiration date and may be amended, suspended or discontinued at any time. Our Board of Directors will periodically evaluate the program and there can be no assurances as to the number of shares of our Common Stock the Company will repurchase.

Table of Contents

Item 6. Exhibits

(a) Exhibits

- 10.1 Cerner Corporation Performance-Based Compensation Plan (As Amended and Restated May 22, 2015) filed as Exhibit 10.1 to Form 8-K filed on May 27, 2015 is incorporated herein by reference as Exhibit 10.1
- 10.2 Cerner Corporation 2011 Omnibus Equity Incentive Plan (As Amended and Restated May 22, 2015) filed as Exhibit 10.2 to Form 8-K filed on May 27, 2015 is incorporated herein by reference as Exhibit 10.2
- 31.1 Certification of Neal L. Patterson pursuant to Section 302 of Sarbanes-Oxley Act of 2002
- 31.2 Certification of Marc G. Naughton pursuant to Section 302 of Sarbanes-Oxley Act of 2002
- 32.1 Certification of Neal L. Patterson pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002
- 32.2 Certification of Marc G. Naughton pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002
- 101.INS XBRL Instance Document
- 101.SCH XBRL Taxonomy Extension Schema Document
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
- 101.LAB XBRL Taxonomy Extension Labels Linkbase Document
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CERNER CORPORATION
Registrant

Date: August 5, 2015

By: /s/ Marc G. Naughton
Marc G. Naughton
Executive Vice President and Chief
Financial Officer (duly authorized
officer and principal financial officer)